Pentobarbital anaesthesia prevents the adrenaline-releasing effect of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin.
Administration of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.25 mg/kg i.v.), to conscious rats increased plasma adrenaline and glucose levels for 30 and 60 min, respectively. Both 8-OH-DPAT-induced changes in plasma adrenaline and glucose levels were totally abolished in pentobarbital-anaesthetized rats. The present data indicate that pentobarbital anaesthesia, a procedure that is commonly used in pharmacological studies, prevents the release of adrenaline evoked by 5-HT1A receptor activation.
Chaouloff
F
F
Laboratoire de Pharmacologie, CNRS, CHU Necker-EM, Paris, France.
Baudrie
V
V
Laude
D
D
D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D000768:Anesthesia, General; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004837:Epinephrine / Q000097:blood / Q000378:metabolism*; D008297:Male; D009281:Naphthalenes / Q000494:pharmacology*; D010424:Pentobarbital; D051381:Rats; D011919:Rats, Inbred Strains; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*
D001786:Blood Glucose; D009281:Naphthalenes; D013764:Tetrahydronaphthalenes; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D010424:Pentobarbital; D004837:Epinephrine